OBJECTIVES:
To compare the use of health care services between patients with private and public drug insurance among users of anti-depressants. METHODS: A matched retrospective cohort study was conducted using databases for Quebec residents with private (reMed database) or public (RAMQ database) drug insurance. The study included 194 reMed and 1923 RAMQ patients aged 18 to 64 years who filled at least one prescription of an antidepressant between December 2007 and September 2009. Patients were matched on age, sex and date of 1st filled prescription of an antidepressant. The primary outcomes were the number of outpatients medical visits, emergency department (ED) visit (yes/no) and hospitalization (yes/ no) for all causes over one year. The secondary outcome was the average antidepressant cost per patient per month. Linear or logistic regression was used to compare the outcomes between patients with private and public drug insurance, while adjusting for potential confounders. RESULTS: Patients with private drug insurance (21.3% males) had 8.1 outpatient medical visits on average, 17.5% had an ED visit and 8.8% were hospitalized over one year. Corresponding figures were 6.6, 20.0% and 8.5% for patients with public drug insurance (23.6% males). Patients with private drug insurance were found to have more outpatient medical visits than patients with public drug insurance (adjusted mean differenceϭ 1.2; 95%CI: 0.2 to 2.3), but were not more likely to have an ED visit (adjusted ORϭ 0.7; 95% CI: 0.5 to 1.1) or a hospitalization (ORϭ0.9; 95%CI: 0.5-1.6). Average cost per patient per month for antidepressants ) for patients with private and public drug insurance, respectively. CONCLUSIONS: Little differences were found in the use of health care services between users of antidepressants with private and public drug insurance, while important differences were observed for the cost of antidepressants.
PHP67 TENDERING FOR OUTPATIENT PRESCRIPTION PHARMACEUTICALS: WHAT CAN BE LEARNED FROM CURRENT PRACTICES IN EUROPE?
Dylst P 1 , Vulto A 2 , Simoens S 3 1 Katholieke Universiteit Leuven, Leuven, Vlaams Brabant, Belgium, 2 Erasmus University Medical center, Hospital Pharmacy, Rotterdam, The Netherlands, 3 K.U. Leuven, Leuven, Belgium OBJECTIVES: To explore the current status (2010) of tendering programs for outpatient pharmaceuticals in the European countries and how these programs operate. METHODS: A survey was designed to assess the features of tendering programs in European countries. All 27 countries of the European Union plus Norway were included in the study. The survey was sent to national representatives of authori-ties and organizations and to academic researchers with expertise in the domain. RESULTS: Nineteen of the 28 countries have responded to the questionnaire (68%). Seven countries have adopted tendering programs for pharmaceuticals in ambulatory care. Tendering was more popular in countries with a mature generic medicines market (54%) than in countries with a developing generic medicines market (12.5%). Authorities with financial interest for possible savings issued the tenders and the lowest price/best offer was amongst the criteria to award the tender in most cases. The frequency varied from only once to once every two weeks and the number of winners was between one and four. The objectives of achieving cost savings were achieved in the short term but results on long term are still unclear. CONCLUSIONS: Tendering programs can achieve savings in the short term, but the effects in the long term are still unclear. It can be concluded that the policy can work, but the features of the programs such as the legal framework, the criteria to grant the tender, the number of winners, the reward of the winner and the frequency, have to be well-thought-out.
PHP68

ASSESSMENT OF THE NHS HOSPITALS' PRODUCTIVITY IN THE REGIONAL HEALTH AUTHORITY OF THESSALY IN GREECE
Androutsou L 1 , Geitona M 2 , Yfantopoulos J 3 1 Ministry of Health and Social Solidarity, Athens, Greece, 2 University of Peloponnese, Athens, Greece, 3 National and Kapodistrian University of Athens, Athens, Greece OBJECTIVES: To assess the performance in seven homogenous specialty clinics across all NHS hospitals in the Regional Health Authority of Thessaly (RHAT), over the period [2002] [2003] [2004] [2005] [2006] . METHODS: Data Envelopment Analysis by using the Malmquist Productivity Index and its decompositions have been applied in order to measure the technical efficiency and productivity. Clinics were considered to transform inputs labour (medical and nursing staff) and capital (hospital beds) into health services, approximated by the number of in-patient discharges and in-patient days, used as outputs. The model is output oriented and assumes variable return to scale. Data were collected from hospitals' records. RESULTS: Overall productivity progressed in all clinics, led by technical change rather than technical efficiency. Over the whole period the size of the clinics influences the overall effects on hospital performance and the maximum level of outputs produced has not been achieved using the given labour and capital inputs, except orthopaedic clinics. The highest productivity changes were achieved by the gynecology (22.5%), the urology (15.7%) and the paediatric clinics (15.4%). All clinics experienced high technological change level, except general medicine clinics which drops by 6.5%. The highest technological changes were experienced by gynecology clinics (48.4%), the paediatrics (26.2%) and ophthalmology (22.1%). CONCLUSIONS: Homogeneity in assessing hospitals' performance provides evidence on the efficiency and productivity gains among clinics and suggests improvements in those which appear inefficient. The difficult economic situation Greece is facing nowadays makes the assessment of NHS hospitals' performance a priority in the decision making. 
PHP69 CAN WE INCREASE HOSPITAL REVENUE WITH DIFFERENT NEUROMUSCULAR BLOCKERS? AN ANALYSIS OF SAVING COST FOR HOSPITAL BUDGET WITH TIME SAVING EFFECT OF DIFFERENT NEUROMUSCULAR BLOCKERS IN SHORT OPERATIONS
OBJECTIVES:
Muscle relaxants are used in anesthesia to obtain adequate muscle relaxation. Our aim is obtaining improvement in hospital budget by selecting adequate neuromuscular blocking agents for short-term (under 60 minutes)pediatric operations for hospital managements. METHODS: There is a basic investigation of the duration to recovery time of atracurium and rocuronium administrations during anesthesia induction in ASA I-II children. In order to evaluate the effect on hospital budget, direct expenses were used. RESULTS: The mean time to reach TOF75 in recovery with rocuronium and atracurium were calculated 38 and 51 minutes, respectively. In atracurium group, time to reach TOF75 was 51 minutes, but operation time was 46 minutes(as rocuronium groups)and patients needed an additional 5 minutes for recovery. During additional minutes, patients were kept in the operation room(OR), thus preparation for the next patient was delayed. After extubation of patients, to determine the period of preparation of an OR for the next patient, a questionnaire was administered. This preparation was determined to be 14 minutes. These means, in the rocuronium and atrocurium groups one needs 60 minutes (46ϩ14) and 65 minutes (51ϩ14), respectively from the start of an operation to the start of next operation. In a pediatric surgery department, lower abdominal and urogenital surgery unit income with rocuronium or atracurium are the same but, rocuronium brings extra time for an average of 15 operations lasting shorter than 1 hour. CONCLUSIONS: Study showed that if a hospital works with 100% performance and has no other problems (shortage of bed,personnel,etc), such a hospital may perform, in a month, an extra 15 pediatric surgical operations less than 1 hour can, by using rocuronium. Thus rocuronium may lead an additional income of US$ 2436 per month for one OR. In other words, in short operations, using rocuronium rather than atracurium may lead to savings which is 30-35% of total cost.
PHP70 VALUE BASED PRICING (VBP): IS THIS THE WAY FORWARD FOR THE UK NHS?
OBJECTIVES: The British government has decided to impose a system of value based pricing (VBP) in England as part of a wide-ranging national health care system (NHS) reform. The outcomes from this decision will have a number of consequences for the NHS and the pharmaceutical industry alike. The objective of this poster is to evaluate the impact of VBP implementation on the NHS and pharmaceutical industry specifically with regards to drug access, health care drug expenditure and promoting innovation. METHODS: A literature review was conducted in order to understand health economists' evaluations about VBP and stakeholders' reaction to proposed reform. Ten stakeholders from academia, the pharmaceutical industry and representative members of the NHS, were involved in qualitative interviews to compare and contrast the views of health care workers, NICE and the pharmaceutical industry about NHS reform and concept of value as it pertains to VBP. RESULTS: VBP as expected has been quite a contentious and controversial issue for the pharmaceutical industry with regards the proposed NHS reform. NICE's position on value based pricing based on cost-effectiveness analyses is arguably not perfect, but it does define outcomes for the pharmaceutical industry in a more transparent manner. Clinician stakeholders, including the proposed GP commissioning groups will have difficulty in determining value without prescribed criteria and specified guidelines based around innovation and value. It is also questionable whether VBP would indeed spur innovation of drug development or in fact hamper research and development due to increased market access requirements and decreased profitability in the pharmaceutical sector. CONCLUSIONS: The definitions of innovation and value in the pharmaceutical industry and the NHS have different meanings for different stakeholders. A clearer understanding of VBP and its expected outcomes would be helpful to bridge the gap between the pharmaceutical industry and the NHS. OBJECTIVES: Syndrome of inappropriate antidiuretic hormone hypersecretion (SIADH) is a common cause of hyponatremia contributing to 30-50% of hyponatremia cases. Little is known of the influence of SIADH on health care resource utilization. This study assessed the effect of SIADH on inpatient total and intensive care unit (ICU) cost and length of stay (LOS), the likelihood of ICU admission, and 30-, 90-, and 180-day readmission. METHODS: The Premier hospital database was utilized to identify US hospital inpatients discharged between January 1, 2007 and June 30, 2009. Hyponatremic/SIADH patients were identified using primary or secondary ICD-9 codes (nϭ430,731) and were matched to a control group (nϭ430,731) using exact matching on age, gender, provider region and 3M™ APR-DRG assignment. Matching was further refined using propensity scores based on additional patient and hospital covariates. Due to the contribution of congestive heart failure and cirrhosis on hyponatremia development, these patients were excluded from the analysis. The final analytic sample contained 65,973 SIADH patients and 407,874 non-hyponatremia/SIADH patients. Cost was analyzed using gamma regression, LOS with negative binomial regression. ICU admission and hospital readmission were analyzed using multivariate logistic regression. RESULTS: In contrast to non-SIADH patients, patients with SIADH had significantly higher total inpatient cost (55. 53%, pϽ.0001), ICU cost (38.07%; pϽ0.0001), total LOS (45.11%, pϽ0.0001), and ICU LOS (42.72%, pϽ.0001) . SIADH patients were significantly more likely to be admitted to the ICU (ORϭ2.131;pϽ.0001), and readmitted at 30-(ORϭ1.399;pϽ0.0001), 90-(ORϭ1.495; pϽ0.0001), and 180-days (ORϭ1.459;pϽ0.0001) in comparison with non-SIADH patients. CONCLUSIONS: The presence of SIADH in hospitalized patients is significantly associated with increased total and ICU cost and LOS, likelihood of ICU admission, and likelihood of readmission. 
PHP71
EFFECT OF SIADH ON PATIENT OUTCOMES AND HEALTH CARE RESOURCE UTILIZATION IN HOSPITALIZED PATIENTS
PHP72
EVIDENCE-BASED PRIORITY SETTING FOR THE NATIONAL HEALTH DEVELOPMENT PLAN OF THAILAND
RESULTS:
Since 1999 there has been an increasing trend in BOD attributable from alcohol and tobacco consumption, consumption of high fat high calorie diet, lack of fibre food and physical activities, increasing incidence of diabetes mellitus, hypertension and high blood lipid, traffic injuries, overweight and obesity. Evidence from the share of DALY loss, productivity loss and absenteeism from morbidity indicates three national health priorities: HIV/AIDS; traffic injuries and diabetes mellitus. Total health expenditure in 2009 was 179 USD per capita, 4.3% of GDP, and mostly spent on curative services, only 4.5% of that was for disease prevention and health promotion. CONCLUSIONS: Thailand can invest more on health of the population, in particular on disease prevention and health promotion to address three national health priorities: HIV/AIDS, traffic injuries and diabetes mellitus through cost effective interventions in and outside the health sector. The most probable scenario for increasing investment in health promotion and disease prevention is to double the amount of investment for health promotion and disease prevention. Also, resources can be mobilized from local administrations and communities, and should be managed by efficient and accountable agency with effective mechanisms.
PHP73 GOVERNMENT REDUCES PUBLIC PHARMACEUTICAL EXPENDITURE IN HUNGARY: RATIONAL DECISIONS IN CHALLENGING ECONOMIC TIMES?
Inotai A 1 , Merész G 1 , Kalo Z 2 1 Syreon Research Institute, Budapest, Hungary, 2 Eötvös Loránd University, Budapest, Hungary OBJECTIVES: Scarcity of public resources, especially in challenging economic times, draws attention to the expenditure on pharmaceuticals. Over the next 3 years the Hungarian government plans to reduce the public pharmaceutical spending by 35%. Our objective was to assess the current level of pharmaceutical expenditure in Hungary by taking into account the economic status of the country and benchmarks from other OECD countries with special focus on Visegrad countries (Czech Republic, Slovakia, Poland, Hungary) . METHODS: We completed international cross sectional and cluster analysis based on OECD Health Data 2010 and longitudinal analysis of public pharmaceutical expenditure in Hungary.
RESULTS:
The cluster analysis indicates that pharmaceutical spending is relatively higher in middle-income countries compared to high income countries above 30'000 USD GDP/capita (1.89 vs. 1.41% of GDP%, pϭ0.04; 23.58% vs. 14.14% of total health expenditure, pϽ0.001), as prices of pharmaceuticals are not adjusted to local price levels as opposed to prices of other health care services. International trends of the global pharmaceutical market are also valid in Hungary. The public pharmaceutical spending is close to the average of Visegrad countries, but the private pharmaceutical spending is the highest. The annual real growth rate of public pharmaceutical spending was only 1.0% between 1994-2010, whilst increased private funding (mainly out of pocket payments) was the major growth driver of total pharmaceutical expenditure in Hungary. CONCLUSIONS: Cost-containment of public pharmaceutical spending was very successful in the last 15 years. The burden of pharmaceutical market growth has been shifted to private households. The proposed public budget cut translates to over 30% decrease in real public pharmaceutical spending from 1994 to 2014. As morbidity and mortality indicators of the Hungarian population are extremely unfavourable, current evidences and international benchmarks do not justify significant reduction of the public pharmaceutical budget. Greek law (3816/2010) sets a list for serious diseases products (89 in total) which can be dispensed either through public hospitals or retail pharmacies for non hospitalized patients. Each distribution channel incurs different costs for the NHS (public hospitals/SSFs). OBJECTIVES: Estimate potential savings for GR NHS (Social Security Funds & Hospitals) through dispensing products of serious diseases through hospital pharmacies instead of retail pharmacies. METHODS: Data derived from drug reimbursement database of OGA (Agriculture SSF) covering 20% of the GR population. The data represent actual reimbursement amounts to private pharmacies, from January to April 2011, extrapolated for the whole 2011. The price calculations were based on the following formulas: 1) Public hospitals buy at hospital price (HP) ϩVAT from pharmaceutical companies; 2) Public hospitals charge wholesaler price ϩ3% premium to SSFs; and 3) Retail pharmacies charge SSFs retail price (calculated as hospital price ϩ2,5%wholesaler margin ϩ18% pharmacy margin ϩVAT). RESULTS: Based on the mean of 5950 prescriptions per month the average value paid by OGA to the retail pharmacies was €1042 per prescription. By changing dispensing channel, via hospital, the mean cost per prescription for OGA was estimated at €930.93. Since both SSFs & hospitals are part of NHS, the actual cost of NHS/prescription is the hospital cost estimated at €818.72 and the estimated hospital gain per prescription is €112.21. The actual gain for NHS per prescription is €223.28. The extrapolated gain for OGA for 2011 is estimated at €7,930.398 while for NHS is €15,942.192. CONCLUSIONS: Distribution of products for serious diseases via hospital pharmacies, leads to considerable savings for NHS and SSFs while ensuring considerable gains for hospitals, under specific conditions (hospital personnel, budget, immediate payment by SSF). The expansion of the list is of absolute priority for reducing the NHS spending. More savings can be achieved by dispensing L3816 products through the newly formed unified health care fund (EOPYY) covering 90% of total population.
PHP74 CONSIDERABLE POTENTIAL SAVINGS FROM CHANGE IN DISTRIBUTION CHANNEL FOR SERIOUS DISEASES PRODUCTS IN GREECE: THE CASE OF OGA SOCIAL SECURITY FUND (SSF)
PHP75 THE COST PER DAY OF INTENSIVE CARE UNITS (ICU) IN FRANCE: THE CRRÉA STUDY
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